Grant Zeng, CFA
Contributor since: 2011
Company: Zacks Investment Research, Inc.
Latest Articles
Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment
Atossa Genetics: Pure Play Breast Care Biotech With Favorable Risk/Reward
The Tumor-Infiltrating Lymphocytes (TILs) And Cancer Therapy
Applied DNA Sciences: An Unique Biotech Company Targeting The Anti-Counterfeiting Market
Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics
OncoSec Medical: Unique Electroporation Technology Delivering Cytokines To Target Cancer
Soligenix: Initiates New Programs To Target Melioidosis
Arrowhead: There Is Still Plenty Of Room For Share Price Appreciation
Two Deals In Two Months: Great Achievement For Advaxis
Pressure BioSciences: A Low Risk, High Reward Stock In The Biotech Space
Lion Biotech: Tumor Infiltrating Lymphocyte Therapy Could Be Paradigm Shift For Treatment Of Melanoma And Other Solid Tumors
Sorrento Therapeutics: Has The Potential To Become Next Abraxis
What Does The Global BioPharma Deal Mean To Advaxis?
Soligenix: Advances Two Lead Programs Into Phase II Within One Week
Novelos Therapeutics: Unique Platform Technology Targets Cancer Imaging And Therapy
If Northwest Biotherapeutics Wins, It Wins Big
DelMar Pharmaceuticals: 2 Major Near-Term Catalysts May Lift Share Price Dramatically
Compelling Phase II Data De-Risks Advaxis
GeneNews: Shifting Focus To ColonSentry Commercialization In The U.S.
Why GeoVax Is Different In The HIV/AIDS Vaccine Space
Pure: Reborn With New Management And Refocused Strategy
ARWR: On Track To Advance ARC-520 For HBV
Tekmira: From A Platform Technology To A Product-Focused Company
Galena: The Launch Of Abstral And Other Important Catalysts
Neogenomics: A Low Risk, High Return Stock To Own
There Are More To Come For Soligenix
Advaxis: First Cancer Vaccine For Cervical Cancer To Be In Pivotal Trial
Soligenix: Poised To Take Off In 2014
Mirati: Reborn After Reincorporation In The U.S. And Nasdaq Listing
Galena: Why We Think There Is More Room For Significant Share Price Appreciation
It May Be An Opportune Time To Consider DelMar Pharma Shares Now
GeneNews: The Market Leader In Colorectal Cancer Molecular Diagnostics